

# HYDROCHLOROTHIAZIDE 5 mg/mL and SPIRONOLACTONE 5 mg/mL ORAL SUSPENSION

Date Prepared:	// 20	LOT: NS
----------------	-------	---------

Expiry Date: \_\_\_\_\_ / \_\_\_\_ / 20\_\_\_\_\_

Final Checked By: \_\_\_\_\_

INGREDIENTS	MFR	LOT #	EXPIRY DATE	FORMULA QUANTITY	QUANTITY USED	PREPARED	CHECKED
Hydrochlorothiazide 25 mg Spironolactone 25 mg tablet	Aldactazide® /Teva			20 tablets			
Ora-Blend				QS to 100 mL			

# **Risk Summary:**

Always follow policies & procedures for risk assessment/NAPRA level as determined by your own pharmacy department.

# Equipment and PPE:

- Mortar and pestle
- Graduated cylinder
- Glass stirring rod
- Standard CHEO Level B PPE (hair bonnet, mask, +/- beard cover, clean gown and nitrile gloves)

# Procedure:

Always follow departments training protocols and policies and procedures that are currently in place.

- 1. Place tablets in mortar and pour a small amount of vehicle over the tablets before levigating.
- 2. Using the pestle, levigate tablets to create a smooth paste.
- **3.** Continue to levigate, adding vehicle in small amounts until the product is liquid enough to transfer to a graduated cylinder.
- 4. Rinse mortar several times with vehicle and add product to the graduated cylinder.
- 5. QS to final volume with vehicle.
- 6. Stir well and transfer to amber bottle, and affix dispensing cap. Label bottle appropriately.
- 7. Before washing, rinse equipment into medication disposal bin, and not directly into sink.

#### **Quality Control:**

- Final Appearance: Opaque white suspension
- Packaging: amber plastic bottles
- Storage & BUD: 60 days in refrigerator, or at room temperature. Protect from light (spironolactone is light sensitive).

#### Sample Label:



Children's Hospital of Eastern Ontario HYDROCHLOROTHIAZIDE 5 mg/mL and SPIRONOLACTONE 5 mg/mL Oral Suspension SHAKE WELL. PROTECT FROM LIGHT. Refrigerate/Room Temperature. Quantity: LOT: Expiry:

# Reference(s):

•Nahata MC, Hipple TF, Pediatric Drug Formulations, 4th ed. 2000, pp 115

•Allen LV, Erickson MA. Stability of labetolol hydrochloride, metoprolol tartrate, verapamil hydrochloride and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids. Am J Health-Syst Pharm. 1996; 53: 2304-9

# Formulation Review:

*Master Formula Revision Dates:* 11 Dec 97; 14 Oct 05; 16 Feb 06; 10 Oct 06; sept 2017; oct 2020 (protect from light): June 21.